Cytek Biosciences, Inc. (CTKB) Financial Statements (2026 and earlier)

Company Profile

Business Address 47215 LAKEVIEW BOULEVARD
FREMONT, CA 94538
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments90,85398,716167,299296,601364,618
Cash and cash equivalent90,85398,716167,299296,601364,618
Restricted cash and investments  293312,899 
Receivables62,50960,58855,92848,86429,760
Inventory, net of allowances, customer advances and progress billings48,42843,89360,87748,15432,171
Inventory48,42843,89360,87748,15432,171
Prepaid expense6,70712,0179,8006,5264,206
Other current assets2,9771,9432,2303,796708
Other undisclosed current assets180,522179,26095,59547,180270
Total current assets:391,996396,446392,060454,020431,733
Noncurrent Assets
Operating lease, right-of-use asset11,31510,16810,85313,883 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization18,00917,96218,40513,6825,851
Long-term investments and receivables  1,6001,6001,600 
Long-term investments  1,6001,6001,600 
Intangible asset, including goodwill, after accumulated amortization33,51836,79139,26714,47514,883
Goodwill16,69716,66316,18310,14410,144
Intangible asset, excluding goodwill, after accumulated amortization16,82120,12823,0844,3314,739
Other noncurrent assets6,7044,7593,3852,9571,665
Other undisclosed noncurrent assets  31,77428,88718,8599,173
Total noncurrent assets:69,546103,054102,39765,45631,572
TOTAL ASSETS:461,542499,500494,457519,476463,305
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:23,41721,44320,03521,12615,251
Employee-related liabilities9,117
Accounts payable6,4105,5293,0324,805 
Accrued liabilities23,41721,44320,03521,126 
Other undisclosed accounts payable and accrued liabilities(6,410)(5,529)(3,032)(4,805)6,134
Deferred revenue28,50425,49222,69512,9867,081
Debt    580 
Other liabilities16,97813,4947,9037,9606,352
Other undisclosed current liabilities8,9057,2345,5936,3884,497
Total current liabilities:77,80467,66356,22649,04033,181
Noncurrent Liabilities
Liabilities, other than long-term debt41,47435,05043,51942,61924,739
Deferred revenue18,33916,09815,13213,1249,790
Estimated litigation liability6,7869,03616,47715,59613,745
Other liabilities2,3072,3642,4311,5871,204
Operating lease, liability14,0427,5529,47912,312 
Other undisclosed noncurrent liabilities5251,0501,6482,271 
Total noncurrent liabilities:41,99936,10045,16744,89024,739
Total liabilities:119,803103,763101,39393,93057,920
Equity
Equity, attributable to parent, including:341,739395,737393,064425,546405,385
Common stock129129131135126
Additional paid in capital441,107430,791423,386442,887423,625
Accumulated other comprehensive income (loss)2,24116(1,275)(697)897
Accumulated deficit(101,738)(35,199)(29,178)(17,030)(19,606)
Other undisclosed equity, attributable to parent    251343
Total equity:341,739395,737393,064425,546405,385
TOTAL LIABILITIES AND EQUITY:461,542499,500494,457519,476463,305

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues201,493200,453193,015164,036127,950
Cost of revenue
(Cost of Product and Service Sold)
(97,033)(89,347)(83,589)(63,062)(48,806)
Gross profit:104,460111,106109,426100,97479,144
Operating expenses(144,844)(131,629)(137,271)(102,778)(69,987)
Operating income (loss):(40,384)(20,523)(27,845)(1,804)9,157
Nonoperating income (expense)10,54314,82312,1363,064(3,219)
Investment income, nonoperating2,2165,1216,4134,61949
Other nonoperating income (expense)8,8014,4637,7941,018(1,527)
Interest and debt expense(474)5,239(2,071)(2,573)(1,741)
Income (loss) from continuing operations before equity method investments, income taxes:(30,315)(461)(17,780)(1,313)4,197
Other undisclosed income (loss) from continuing operations before income taxes474(5,239)2,0712,5731,741
Income (loss) from continuing operations before income taxes:(29,841)(5,700)(15,709)1,2605,938
Income tax expense (benefit)(36,698)(320)3,5611,224(2,911)
Income (loss) from continuing operations:(66,539)(6,020)(12,148)2,4843,027
Income before gain (loss) on sale of properties:3,027
Net income (loss):(66,539)(6,020)(12,148)2,4843,027
Net loss attributable to noncontrolling interest    (92)(26)
Other undisclosed net income attributable to parent   9226
Net income (loss) attributable to parent:(66,539)(6,020)(12,148)2,4843,027
Undistributed earnings (loss) allocated to participating securities, basic     3,001
Other undisclosed net income available to common stockholders, basic    92 
Net income (loss) available to common stockholders, diluted:(66,539)(6,020)(12,148)2,5766,028

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net income (loss):(66,539)(6,020)(12,148)2,4843,027
Comprehensive income (loss):(66,539)(6,020)(12,148)2,4843,027
Comprehensive income (loss), net of tax, attributable to noncontrolling interest   (236)92(317)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2,2251,290(342)(1,686)1,149
Comprehensive income (loss), net of tax, attributable to parent:(64,314)(4,730)(12,726)8903,859

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: